• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Metabolism. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

tetano

Editor, Senior Moderator
Metabolism. 2020 Apr 19:154244. doi: 10.1016/j.metabol.2020.154244. [Epub ahead of print]
Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.


Zheng KI[SUP]1[/SUP], Gao F[SUP]2[/SUP], Wang XB[SUP]3[/SUP], Sun QF[SUP]4[/SUP], Pan KH[SUP]5[/SUP], Wang TY[SUP]6[/SUP], Ma HL[SUP]1[/SUP], Liu WY[SUP]7[/SUP], George J[SUP]8[/SUP], Zheng MH[SUP]9[/SUP].

Author information




Abstract

BACKGROUND & AIMS:

Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity.
METHODS:

214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25 kg/m[SUP]2[/SUP].
RESULTS:

The presence of obesity in MAFLD patients was associated with a ~ 6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p = .029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p = .033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia.
CONCLUSIONS:

Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.
Copyright ? 2020. Published by Elsevier Inc.



KEYWORDS:

COVID-19; MAFLD; Obesity; SARS-CoV-2


PMID:32320741DOI:10.1016/j.metabol.2020.154244
 
Back
Top Bottom